­

About admin

This author has not yet filled in any details.
So far admin has created 96 blog entries.

OncBioMune Appoints Robert Neal Holcomb to Board of Directors

BATON ROUGE, La., March 19, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer

BATON ROUGE, La., March 08, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas

BATON ROUGE, La., Feb. 28, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Provides Updates on Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer

BATON ROUGE, La., Feb. 26, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas

BATON ROUGE, La., Feb. 05, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time

BATON ROUGE, La., January 10, 2018 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged [...]

One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial

100% Overall Survival Rate in 14 Evaluable Patients at One-Year Follow-Up BATON ROUGE, La., Dec. 21, 2017 -- OncBioMune Pharmaceuticals, [...]

100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression

BATON ROUGE, La., Dec. 05, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged [...]

80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up

BATON ROUGE, La., Nov. 13, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged [...]

OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine

BATON ROUGE, La., Oct. 17, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged [...]